The global breast biopsy devices market size was valued at USD 1.94 billion in 2025 and is projected to grow from USD 2.07 billion in 2026 to USD 3.43 billion by 2034, registering a CAGR of 6.54% during the forecast period (2026-2034). North America dominated the breast biopsy devices market with a share of 43.75% in 2025.
Breast biopsy devices are medical instruments used to collect tissue samples from suspicious breast lesions for diagnostic examination. These devices include core needle biopsy systems, vacuum-assisted biopsy systems, and fine-needle aspiration devices. Breast biopsy needles fall under HSN Code 9018.32 (tubular metal needles), while biopsy instruments are classified under SIC Code 3841 (surgical and medical instruments and apparatus).
The breast biopsy devices market demand is driven by increasing breast cancer screening and the need for accurate tissue diagnosis. Preference for minimally invasive, image-guided biopsy procedures, and vacuum-assisted systems supports breast biopsy devices market growth.
Download a Free Sample To learn more about this report,
Supply chain disruptions are expected to have a moderate impact on the breast biopsy devices market share due to shortages of biopsy needles, medical-grade materials, and specialized components. The market is expected to experience a K-shaped recovery, as established manufacturers can maintain supply through diversified production networks. Smaller manufacturers remain more exposed to component shortages and procurement delays. The market is projected to grow at a CAGR of 6.54%. Supply constraints could temporarily reduce growth by an illustrative 1.4 percentage points to 5.14%. Improved component availability and manufacturing capacity are expected to support a gradual return to 6.54% growth.
Adoption of Contrast-Enhanced Breast Biopsy
The breast biopsy devices market analysis indicates increasing adoption of contrast-enhanced mammography-guided biopsy systems for sampling suspicious breast lesions. These systems help radiologists identify lesions that are difficult to detect through conventional imaging. For example, Hologic and GE HealthCare offer breast imaging and biopsy solutions that support image-guided breast diagnostic procedures.
Integration of MRI-Compatible Vacuum-Assisted Biopsy Systems
MRI-compatible vacuum-assisted biopsy systems are gaining attention for sampling breast lesions that are difficult to identify through conventional imaging. Manufacturers are developing compact systems suitable for use inside MRI examination rooms. These devices allow clinicians to collect tissue samples while remaining close to the patient.
In April 2026, Merit Medical Systems acquired View Point Medical for approximately USD 140 million, including assumed liabilities. View Point develops the OneMark Detection Imaging System and tissue markers that help localize breast and soft-tissue lesions around biopsy and subsequent treatment.
Detection of Breast Abnormalities through Advanced Screening and Demand for Single-Use Breast Biopsy Instruments Drives Market
Wider use of digital breast tomosynthesis is increasing the detection of abnormalities requiring diagnostic evaluation. Improved imaging helps identify small lesions that may need image-guided tissue sampling. The FDA's breast density reporting requirements have also strengthened awareness of additional diagnostic assessment. These developments support demand for stereotactic and ultrasound-guided biopsy devices, particularly in breast imaging centers handling suspicious mammography findings.
Preference for single-use breast biopsy instruments is strengthening demand for disposable biopsy needles and sampling accessories. Healthcare facilities require sterile instruments for each procedure to minimize cross-contamination risks. Single-use devices eliminate the need for cleaning and sterilization between procedures, reducing equipment turnaround time. The use of disposable components in core needle biopsy systems supports recurring product demand and steady revenue generation for breast biopsy device manufacturers.
Shortage of Specialized Biopsy Needles and High Equipment Costs and Limited MRI-Guided Biopsy Access Restrain Market Growth
Limited availability of specialized breast biopsy needles is affecting procedure scheduling and device utilization. Healthcare facilities depend on compatible disposable needles for stereotactic biopsy systems. Supply disruptions can delay tissue sampling and increase procurement difficulties. The U.S. FDA has identified a shortage of stereotactic breast biopsy needles, with the disruption expected to continue through the first quarter of 2027.
MRI-guided breast biopsy requires specialized equipment and trained radiologists, increasing the financial burden on diagnostic facilities. Smaller hospitals may face difficulties establishing dedicated biopsy services due to equipment and maintenance expenses. The American College of Radiology recognizes that limited access to MRI-guided biopsy can require patients to undergo repeat imaging at another facility.
Expansion of Advanced Vacuum-Assisted Tissue Sampling Systems and Development of Advanced Breast Biopsy Site Markers Creates Growth Opportunities
Advancements in vacuum-assisted biopsy technology are creating opportunities for manufacturers to improve tissue collection efficiency. These systems allow multiple samples to be collected through a single needle insertion, reducing repeated needle placement. According to RadiologyInfo, a service of the American College of Radiology and Radiological Society of North America, vacuum-assisted procedures typically collect 8–10 tissue samples.
Development of advanced breast biopsy site markers is creating opportunities for manufacturers to improve lesion localization after tissue sampling. Hydrogel-based markers offer improved visibility during ultrasound examinations and help identify previously biopsied areas. These markers also support accurate localization when lesions become difficult to identify after treatment. Manufacturers can expand their portfolios with nonmetallic and migration-resistant markers, supporting demand for specialized breast biopsy accessories.
In 2025, biopsy guidance systems had a share of 24.50%, supported by rising utilization of stereotactic guidance for precise needle positioning during breast tissue sampling. The need for accurate targeting of small microcalcifications supports adoption across specialized breast diagnostic facilities.
The biopsy needles segment is projected to undergo growth at a CAGR of 7.42% during the forecast period, driven by the need for different needle gauges across tissue sampling procedures. Compatibility with automated core biopsy guns supports specialized needle selection for specific breast lesions.
Request Customizationto receive a tailored report.
Early cancer screening dominated the application segment in 2025, accounting for a share of 62.50%. This dominance is attributed to increasing number of tissue sampling procedures following abnormal mammography findings. The need to confirm suspicious calcifications supports continued utilization of breast biopsy devies.
Therapy selection is anticipated to record a growth rate of 6.42% during the forecast period. This growth is fueled by the use of biopsy tissue for breast cancer biomarker assessment. The importance of estrogen receptor and HER2 testing in treatment planning supports demand for adequate tissue samples.
By end user, hospitals accounted for a dominant share of 55.80% in 2025, owing to their established infrastructure for managing complex breast biopsy procedures. The availability of surgical support and onsite pathology departments strengthens their position as preferred facilities for complicated diagnostic cases.
The imaging & diagnostic centers segment is expected to experience a growth rate of 7.48% during the forecast period. This growth is supported by expansion of outpatient breast biopsy services. The increasing availability of dedicated ultrasound-guided biopsy facilities enables faster appointment scheduling and supports higher volumes of diagnostic procedures.
Speak to an Analystto discuss market opportunities.
The North America breast biopsy devices market accounted for the largest regional share of 43.75% in 2025.
Centers for Medicare & Medicaid Services covers stereotactic and ultrasound-guided biopsy for eligible non-palpable breast abnormalities classified as BI-RADS III, IV, or V. This coverage supports utilization of dedicated guidance systems and biopsy needles across outpatient diagnostic facilities. Established reimbursement pathways also encourage continued procurement of compatible biopsy instruments.
Canadian Partnership Against Cancer recommends percutaneous core needle biopsy as the preferred diagnostic approach over open surgical biopsy. Ontario's breast screening program also provides structured referrals for further assessment of abnormal findings. These practices support demand for core biopsy needles and image-guided sampling equipment across specialized diagnostic facilities.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific breast biopsy devices market is expected to grow at a CAGR of 8.59% during the forecast period, showcasing the fastest-growing regional market.
China's National Health Commission reports an established service pathway covering screening, diagnosis, treatment and follow-up. Referral of suspicious breast findings to higher-level medical institutions creates opportunities for ultrasound-guided biopsy equipment. The program's emphasis on strengthening clinical training also supports more consistent use of tissue sampling procedures.
Ministry of Health and Family Welfare recommends ultrasound examination followed by biopsy for suspicious breast findings. Its Free Diagnostics Service Initiative also identifies fine-needle aspiration biopsy as a confirmatory diagnostic procedure. These provisions support demand for biopsy needles across public healthcare facilities.
Japan's National Cancer Center identifies additional mammography, ultrasound examination and needle-based tissue sampling as established methods for evaluating suspicious findings. The use of ultrasound to examine localized breast abnormalities supports demand for compatible core biopsy instruments. Specialized hospitals also require reliable tissue collection systems to confirm diagnoses before treatment planning.
The Europe breast biopsy devices market is expected to grow at a CAGR of 5.94% during the forecast period.
NHS Breast Screening Program emphasizes on accurate tissue diagnosis through image-guided procedures. NHS England's clinical guidelines recommend core needle or vacuum-assisted biopsy for significant breast abnormalities. The guidelines also specify ultrasound as the preferred guidance method for needle sampling. These established clinical practices support demand for biopsy instruments and compatible imaging guidance systems across NHS breast assessment centers.
Germany's Kooperationsgemeinschaft Mammographie oversees 95 certified screening units serving more than 10 million eligible women nationwide. Suspicious screening findings requiring tissue confirmation support demand for core needle and vacuum-assisted biopsy devices. Regular quality assessments also encourage the use of reliable biopsy equipment across specialized breast diagnostic facilities.
The Latin America breast biopsy devices market is expected to grow at a CAGR of 6.85% during the forecast period. Brazil's National Cancer Institute (INCA) identifies core needle and vacuum-assisted biopsy as preferred methods for breast cancer diagnosis. The country's established diagnostic guidelines are expected to strengthen demand for image-guided biopsy systems and compatible sampling instruments.
Mexico is strengthening breast diagnostic infrastructure through the Mexican Social Security Institute (IMSS). The institute has acquired 67 mammography systems, including 37 with stereotactic capabilities, for deployment across healthcare facilities. Its Acto Único strategy also enables eligible patients to undergo breast imaging and biopsy during a single visit.
The Middle East & Africa breast biopsy devices market is expected to grow at a CAGR of 7.18% during the forecast period. UAE's Department of Health has designated three Oncology Centres of Excellence for Breast Cancer. Cleveland Clinic Abu Dhabi provides MRI-guided and vacuum-assisted biopsy services, supporting demand for specialized breast biopsy equipment.
South Africa is strengthening public breast diagnostic services through specialized hospital infrastructure. The Gauteng Department of Health has upgraded the Breast Centre for Excellence at Helen Joseph Hospital to provide comprehensive diagnostic and treatment services.
The breast biopsy devices market competitive landscape is moderately consolidated, comprising multinational companies, biopsy equipment manufacturers, and regional suppliers. Key players such as Hologic, Mammotome, BD, Argon, Merit Medical, and Cook Medical are estimated to account for over 50% of the global breast biopsy devices market share.
Established players compete primarily on image-guided precision, regulatory approvals, and product innovation. Emerging and regional players in the breast biopsy devices market ecosystem compete through cost-effective biopsy needles, minimally invasive solutions, and localized distribution partnerships.
August 2026: Hologic received FDA 510(k) clearance for its Brevera 9G biopsy needle.
June 2026: Mammotome obtained CE marking for its HydroMARK Plus Breast Biopsy Site Marker.
April 2026: Blackstone and TPG completed the acquisition of Hologic, a manufacturer of breast biopsy systems, with a transaction value of up to USD 18.3 billion.
March 2026: Mammotome received FDA clearance for its Prima MR Dual Vacuum-Assisted Breast Biopsy System and HydroMARK Plus MR Biopsy Site Markers
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Electrophysiology Market Size, Forecast, Opportunities, 2034
Blood Glucose Monitoring Devices Market Size, Forecast, Demand, Opportunities, 2034
Autoclaves Market Size, Forecast, Demand, Opportunities, 2034
X-Ray Detector Market Size, Share, Growth, Analysis, Report, 2034
Blood Pressure Transducers Market Size, Forecast, Opportunities, 2034
3D Printed Prosthetics Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com